Equities research analysts predict that Inspire Medical Systems (NASDAQ:INSP) will report $14.00 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Inspire Medical Systems’ earnings, with the highest sales estimate coming in at $14.10 million and the lowest estimate coming in at $13.90 million. The business is expected to issue its next earnings results on Tuesday, February 5th.
According to Zacks, analysts expect that Inspire Medical Systems will report full year sales of $48.00 million for the current year, with estimates ranging from $47.90 million to $48.10 million. For the next fiscal year, analysts forecast that the business will post sales of $63.33 million, with estimates ranging from $61.20 million to $64.50 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Inspire Medical Systems.
Inspire Medical Systems (NASDAQ:INSP) last posted its earnings results on Tuesday, November 6th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.13. The firm had revenue of $13.10 million during the quarter, compared to analyst estimates of $12.86 million. During the same period in the previous year, the company posted ($3.42) EPS. Inspire Medical Systems’s revenue for the quarter was up 79.9% compared to the same quarter last year.
In related news, Director Jerry C. Griffin sold 1,300 shares of the stock in a transaction that occurred on Tuesday, December 11th. The stock was sold at an average price of $37.60, for a total transaction of $48,880.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Timothy P. Herbert sold 15,000 shares of the stock in a transaction that occurred on Tuesday, December 18th. The stock was sold at an average price of $42.88, for a total value of $643,200.00. The disclosure for this sale can be found here. Insiders have sold 41,300 shares of company stock worth $1,694,130 in the last three months.
A number of large investors have recently modified their holdings of the stock. Orbimed Advisors LLC bought a new stake in Inspire Medical Systems during the second quarter worth $87,161,000. Millennium Management LLC bought a new stake in Inspire Medical Systems during the second quarter worth $26,752,000. BlackRock Inc. bought a new stake in Inspire Medical Systems during the second quarter worth $19,624,000. FMR LLC bought a new stake in Inspire Medical Systems during the second quarter worth $11,340,000. Finally, Federated Investors Inc. PA bought a new stake in Inspire Medical Systems during the second quarter worth $10,949,000.
Shares of Inspire Medical Systems stock traded down $0.08 on Thursday, hitting $41.95. The stock had a trading volume of 136,310 shares, compared to its average volume of 207,312. Inspire Medical Systems has a twelve month low of $22.50 and a twelve month high of $57.87.
About Inspire Medical Systems
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
Recommended Story: Why is the Consumer Price Index (CPI) important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.